- Home
- RLAY vs FTAIM Comparison
RLAY vs FTAIM Comparison
Compare RLAY & FTAIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
FTAIM
FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
Current Price
Company Overview
Basic Information| Metric | RLAY | FTAIM |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | 580 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Corporate Leasing Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | N/A |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLAY | FTAIM |
|---|---|---|
| Price | $8.01 | $26.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | N/A |
| Earning Date | 11-06-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $20.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | N/A |
| 52 Week High | $8.70 | N/A |
Technical Indicators
Market Signals| Indicator | RLAY | FTAIM |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 53.15 |
| Support Level | $7.42 | $26.80 |
| Resistance Level | $8.00 | $26.81 |
| Average True Range (ATR) | 0.52 | 0.13 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 65.26 | 62.71 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About FTAIM FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.